Back to my company list

Rosetta Omics

The AI engine Fit Assessment

Beta

The company effectively leverages machine learning for biomarker identification and the development of new therapeutic strategies, enhancing personalized medicine in oncology.

Blurb

Rosetta Omics diagnoses and stratifies first-line cancer treatment options for oncologists, clinicians, and pathologists.

HQ Location

France

Founded

2022

Employees

1 - 10

Total funding raised

Not available

Last Funding Event

Non-Equity Assistance, May 1, 2024

Smart insights

  • Catherine Msc (Chief People Officer) worked at Lilium as Head of People Business Partnering for 1.5 years (2021 - 2022)
  • Val Miftakhov (Founder & CEO) worked at Google in various roles, including Head of R&D, Google for Work Incubation, for a total of 4 years (2012 - 2016)
  • 6m headcount growth: 25%
  • 1Y headcount growth: 94%
  • Headcount-to-last-round ratio: 5.3 employees/$M
Subspaces
  • Biomarker Identification

Operator of a biotechnology company intended to unlock the road to precision medicine in oncology by tumor characterization via high-resolution proteomic profiling via the combined use of mass spectrometry imaging and machine learning algorithms. The company focuses on personalized medicine by offering patients the right treatment at the right time, especially for poor prognosis cancers like digestive cancers, enabling better patient management and saving billions of money for the healthcare systems.